In the last trading session, 32.24 million shares of the Channel Therapeutics Corporation (AMEX:CHRO) were traded. Most recently the company’s share price was $2.66, and it changed around $0.76 or 40.00% from the last close, which brings the market valuation of the company to $16.04M. CHRO currently trades at a discount to its 52-week high of $6.00, offering almost -125.56% off that amount. The share price’s 52-week low was $0.45, which indicates that the current value has risen by an impressive 83.08% since then. We note from Channel Therapeutics Corporation’s average daily trading volume that its 10-day average is 1.55 million shares, with the 3-month average coming to 350.72K.

Channel Therapeutics Corporation stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CHRO as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.

Channel Therapeutics Corporation (AMEX:CHRO) trade information

Instantly CHRO has showed a green trend with a performance of 40.00% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.8000 on recent trading dayincreased the stock’s daily price by 30.0%. The company’s shares are currently up 314.98% year-to-date, but still up 195.56% over the last five days. On the other hand, Channel Therapeutics Corporation (AMEX:CHRO) is 329.38% up in the 30-day period. We can see from the shorts that 58233.0 shares have been sold at a short interest cover period of 0.26 day(s).

CHRO Dividends

Channel Therapeutics Corporation’s next quarterly earnings report is expected to be released in February.